Loading...
Market
GSK mRNA flu vaccine launch by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
GSK official announcements and press releases
Story
GSK Acquires Full Rights to Develop mRNA Flu and COVID-19 Vaccines from CureVac for €1.4 Billion
Jul 3, 2024, 07:27 AM
GSK and CureVac have restructured their collaboration into a new licensing agreement. As part of the deal, GSK will acquire full rights to develop and manufacture mRNA flu and COVID-19 shots from CureVac. The agreement includes a payment of up to €1.4 billion.
View original story
Similar markets
Positive • 33%
Neutral • 33%
Negative • 33%
Under $500 million • 33%
$500 million - $1 billion • 33%
Over $1 billion • 33%
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
